Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions [0.03%]
水凝胶的潜在医疗应用：现状与未来方向研究进展
Peilin Lu,Dongxue Ruan,Meiqi Huang et al.
Peilin Lu et al.
The applications of hydrogels have expanded significantly due to their versatile, highly tunable properties and breakthroughs in biomaterial technologies. In this review, we cover the major achievements and the potential of hydrogels in the...
Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma [0.03%]
阿法替尼（酪氨酸激酶抑制剂）治疗EGFR高表达的食管鳞癌细胞株的临床疗效及其耐药相关因素的鉴定
Yanni Wang,Chang Liu,Huan Chen et al.
Yanni Wang et al.
Epidermal growth factor receptor (EGFR) is reportedly overexpressed in most esophageal squamous cell carcinoma (ESCC) patients, but anti-EGFR treatments offer limited survival benefits. Our preclinical data showed the promising antitumor ac...
A Cullin 5-based complex serves as an essential modulator of ORF9b stability in SARS-CoV-2 replication [0.03%]
一个Cul5基于的复合物作为SARS-CoV-2复制中ORF9b稳定性的必需调节因子
Yuzheng Zhou,Zongpeng Chen,Sijie Liu et al.
Yuzheng Zhou et al.
The ORF9b protein, derived from the nucleocapsid's open-reading frame in both SARS-CoV and SARS-CoV-2, serves as an accessory protein crucial for viral immune evasion by inhibiting the innate immune response. Despite its significance, the p...
Targeting a disintegrin and metalloprotease (ADAM) 17-CD122 axis enhances CD8+ T cell effector differentiation and anti-tumor immunity [0.03%]
靶向ADAM17-CD122轴可增强CD8⁺T细胞效应分化和抗肿瘤免疫
Lina Sun,Anjun Jiao,Haiyan Liu et al.
Lina Sun et al.
CD8+ T cell immune responses are regulated by multi-layer networks, while the post-translational regulation remains largely unknown. Transmembrane ectodomain shedding is an important post-translational process orchestrating receptor express...
Pre-activated macrophage membrane-encased aggregation-induced emission featuring nanoparticles: a novel possibility for tuberculosis treatment [0.03%]
用于结核病治疗的聚集诱导发光特性纳米颗粒包封预活化巨噬细胞膜的新思路
Qiang Cai,Yihao Tian,Quazi T H Shubhra
Qiang Cai
Engineered extracellular vesicles for targeted reprogramming of cancer-associated fibroblasts to potentiate therapy of pancreatic cancer [0.03%]
工程化细胞外囊泡靶向重编程癌症相关成纤维细胞增强胰腺癌治疗效果
Pengcheng Zhou,Xuanlong Du,Weilu Jia et al.
Pengcheng Zhou et al.
Pancreatic cancer is one of the deadly malignancies with a significant mortality rate and there are currently few therapeutic options for it. The tumor microenvironment (TME) in pancreatic cancer, distinguished by fibrosis and the existence...
From the unknown to spotlight: newly identified hormone adjusts hepatic cholesterol synthesis to dietary uptake [0.03%]
从无到有：新发现的激素调控肝脏胆固醇生物合成以适应饮食摄入变化
Yakum Bertrand Nkeh,Resul Gökberk Elgin,Gesine Saher
Yakum Bertrand Nkeh
Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection [0.03%]
优化RNA干扰疗法联合白细胞介素-2信使核糖核酸治疗乙型肝炎病毒感染
Wenjing Zai,Min Yang,Kuan Jiang et al.
Wenjing Zai et al.
This study aimed to develop a pan-genotypic and multifunctional small interfering RNA (siRNA) against hepatitis B virus (HBV) with an efficient delivery system for treating chronic hepatitis B (CHB), and explore combined RNA interference (R...
Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets [0.03%]
肿瘤的启动和早期发生：分子机制和干预靶点
Shaosen Zhang,Xinyi Xiao,Yonglin Yi et al.
Shaosen Zhang et al.
Tumorigenesis is a multistep process, with oncogenic mutations in a normal cell conferring clonal advantage as the initial event. However, despite pervasive somatic mutations and clonal expansion in normal tissues, their transformation into...
Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study [0.03%]
派安普利单抗治疗复发或转移性鼻咽癌患者的II期临床试验
Xiaozhong Chen,Wei Wang,Qingfeng Zou et al.
Xiaozhong Chen et al.
Penpulimab is an anti-programmed cell death-1 (PD-1) IgG1 antibody with no Fc gamma receptor (FcγR) binding activity, and thus theoretically reduced immune-related adverse events (irAEs) while maintaining efficacy. This single-arm, phase I...